These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20597877)

  • 1. Renzapride in IBS: is efficacy in the eye of the beholder?
    Ford AC
    Aliment Pharmacol Ther; 2010 Jul; 32(1):113-4; author reply 114-5. PubMed ID: 20597877
    [No Abstract]   [Full Text] [Related]  

  • 2. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
    Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
    George AM; Meyers NL; Hickling RI
    Aliment Pharmacol Ther; 2008 May; 27(9):830-7. PubMed ID: 18284648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial.
    Spiller RC; Meyers NL; Hickling RI
    Dig Dis Sci; 2008 Dec; 53(12):3191-200. PubMed ID: 18465239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
    Camilleri M; McKinzie S; Fox J; Foxx-Orenstein A; Burton D; Thomforde G; Baxter K; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):895-904. PubMed ID: 15476153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study.
    Lembo AJ; Cremonini F; Meyers N; Hickling R
    Aliment Pharmacol Ther; 2010 May; 31(9):979-90. PubMed ID: 20163375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome.
    Scarpellini E; Tack J
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1663-70. PubMed ID: 18922103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.
    Meyers NL; Hickling RI
    J Int Med Res; 2007; 35(6):848-66. PubMed ID: 18034998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.
    Meyers NL; Hickling RI
    Drugs R D; 2008; 9(1):37-63. PubMed ID: 18095752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials in irritable bowel syndrome: a review.
    Ervin CM; Mangel AW
    Rev Recent Clin Trials; 2013 Mar; 8(1):9-22. PubMed ID: 23130604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New drugs for the treatment of constipation].
    Adam B; Liebregts T; Gerken G
    Med Klin (Munich); 2010 Jul; 105(7):475-8. PubMed ID: 20676949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
    Schoenfeld P
    Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LAS 30451: a novel 5-HT3 antagonist.
    Martin M; Rosell R; Guillem V; Díaz-Rubio E; Moreno I; Soriano V; Fernández A; Pérez A
    Eur J Cancer; 1993; 29A Suppl 1():S33-4. PubMed ID: 8427723
    [No Abstract]   [Full Text] [Related]  

  • 14. Zacopride in schizophrenia: a single-blind serotonin type 3 antagonist trial.
    Newcomer JW; Faustman WO; Zipursky RB; Csernansky JG
    Arch Gen Psychiatry; 1992 Sep; 49(9):751-2. PubMed ID: 1514881
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis.
    Mackie AD; Ferrington C; Cowan S; Merrick MV; Baird JD; Palmer KR
    Aliment Pharmacol Ther; 1991 Apr; 5(2):135-42. PubMed ID: 1888816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revival of 5-HT3 antagonism as treatment of IBS-D?
    Barbara G
    Gut; 2014 Oct; 63(10):1530-2. PubMed ID: 24465028
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
    Hirata T; Funatsu T; Keto Y; Akuzawa S; Akiho H; Nishida A; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2009 May; 133(5):281-91. PubMed ID: 19443966
    [No Abstract]   [Full Text] [Related]  

  • 18. Zatosetron. (LY 191617, LY 277359).
    Drugs R D; 1999 Dec; 2(6):397-9. PubMed ID: 10763451
    [No Abstract]   [Full Text] [Related]  

  • 19. Peripherally acting therapies for the treatment of irritable bowel syndrome.
    Saad RJ
    Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antiemetic for irritable bowel syndrome?
    Levy R; Corbo J; Prasad S
    J Fam Pract; 2014 Oct; 63(10):600-2. PubMed ID: 25343149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.